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Prostate cancer (CaP) is the most commonly diagnosed and the second leading cause of death from cancer in
males in USA. Prostate orthotopic mouse model has been widely used to study human CaP in preclinical settings.
Measurement of changes in tumor size obtained from noninvasive diagnostic images is a standard method for
monitoring responses to anticancer modalities. This article reports for the first time the usage of a three-
dimensional (3D) ultrasound system equipped with photoacoustic (PA) imaging in monitoring longitudinal prostate
tumor growth in a PC-3 orthotopic NODSCID mouse model (n = 8). Two-dimensional and 3D modes of ultrasound
show great ability in accurately depicting the size and shape of prostate tumors. PA function on two-dimensional
and 3D images showed average oxygen saturation and average hemoglobin concentration of the tumor. Results
showed a good fit in representative exponential tumor growth curves (n = 3; r2 = 0.948, 0.955, and 0.953,
respectively) and a good correlation of tumor volume measurements performed in vivo with autopsy (n = 8, r =
0.95, P b .001). The application of 3D ultrasound imaging proved to be a useful imaging modality in monitoring
tumor growth in an orthotopic mouse model, with advantages such as high contrast, uncomplicated protocols,
economical equipment, and nonharmfulness to animals. PA mode also enabled display of blood oxygenation
surrounding the tumor and tumor vasculature and angiogenesis, making 3D ultrasound imaging an ideal tool for
preclinical cancer research.
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Prostate cancer (CaP) is the most commonly diagnosed and the second
leading cause of death from cancer in males in USA in 2014 [1]. Because
CaP does not occur naturally in small rodents, mouse models are often
established by subcutaneous and orthotopic injection of human CaP cells
into immune-compromised mice. Mouse models play very important
roles in CaP research. In preclinical oncology research, measurements of
changes in tumor size obtained from diagnostic images are a standard
method for monitoring responses to anticancer therapies [2]. For the
orthotopic model which is broadly used in CaP research, it is very difficult
to palpate the tumors and measure tumor growth, largely limiting the
application of this model.
The recent development of noninvasive high-resolution imaging
technologies for use with small laboratory animals has made
equivalent measurements possible in mouse cancer models [3].Ultrasound is a nonionizing and noninvasive imaging technique and
provides good soft-tissue contrast and high spatial resolution without
the need for administration of contrast agents, which makes itself an
ideal tool for CaP imaging. Ultrasound is a quick, inexpensive, and
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obtained within 5 mm of the detector [4]. Despite the noninvasive
and practical property of ultrasound, one of the major limitations of
conventional ultrasound images is their inherently two-dimensional
(2D) character because human anatomy is three-dimensional (3D).
Thus, the specificity and accuracy of conventional 2D ultrasound are
not satisfactory, being an arduous and time-consuming process prone
to operator variability. 3D ultrasound imaging could significantly
improve the accuracy and efficacy of tumor volume measurements
obtained. Moreover, the recent development of photoacoustic (PA)
imaging of tissues has demonstrated the ability to resolve common
chromophores with spatial resolution exceeding that of ultrasound
[5]. PA images relied on the endogenous contrast offered by blood
and were presented as either a map of hemoglobin concentration or
oxygen saturation (sO2) based on the approximations [6]. Conse-
quently, it enables imaging of vascular structures [5], blood
oxygenation [7], and tumor angiogenesis [8].
In this study, we established the CaP orthotopic animal model
using NODSCID mice, followed by longitudinal imaging studies
which for the first time showed the feasibility and sensitivity of 3D
ultrasound for monitoring prostate tumor growth in mice, and
illustrate the use of PA ultrasound imaging to detect the tumor
microenvironment of CaP in NODSCID mice.
Material and Methods
Cell Line and Cell Culture
PC-3 CaP cell line was cultured in RPMI-1640 supplemented
with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), 50 U/
ml of penicillin, and 50U/ml of streptomycin. Cells were maintained
in a humidified incubator at 37°C and 5% CO2. All cell culture
reagents were supplied by Invitrogen Australia Pty Ltd (Melbourne,
VIC, Australia) unless otherwise stated. The identity of PC-3 was
confirmed by short tandem repeat profiling and was tested within a
few passages of initial authentication. The cell line was regularly
tested to confirm the absence of mycoplasma contamination using
the LookOut mycoplasma PCR detection kit (Sigma-Aldrich Pty
Ltd, NSW, Australia).
Establishment of Orthotopic Xenograft Animal Model
Eight male, 6-week-old NODSCID mice (Animal Resources Centre,
WA, Australia) were housed under specific pathogen-free conditions in
facilities approved by the University of New South Wales Animal Care
and Ethics Committee (ACEC Ethics No. 14/46A). Mice were kept at
least 1week before experimentalmanipulation. Allmice remained healthy
and active during the experiment. As described previously [9], mice were
anesthetized with 2% isoflurane in oxygen, and 1 × 106 PC-3 CaP cells
suspended in 50μl ofDulbecco’s phosphate-buffered saline (DPBS) were
injected into the ventral prostatic lobe after exposure through a lower
midline laparotomy incision. After the cell inoculation, prostate and other
organs were returned to the body cavity, and incision was closed with
sutures and metal clips. Starting from the first week after cell inoculation
when the incision achieved a satisfactory healing and metal clips were
removed, tumor progression was monitored weekly by ultrasound.
Ultrasonic Imaging Acquisition and Analysis
Mice were anesthetized with 1.5% to 2% isoflurane in oxygen and
restrained on a heated stage during imaging. Prewarmed ultrasound
coupling gel (Aquasonic 100, Parker Laboratories, Inc., Fairfield, NJ)was applied to the depilated skin before the imaging. Ultrasound
imaging scan was performed using VisualSonics Vevo 2100
Ultrasound (VisualSonics Inc., Ontario, Canada). 2D images of
mouse prostate and neighbor anatomies were acquired using a
linear-array transducer (MS-400) in B-mode with 30-MHz center
frequency that produces a 15-mm*15-mm field of view at the 12-mm
focal depth. In the 3D acquisition method, the probe was attached to
a 3D scanning motor that linearly drove the ultrasound probe across
the mouse’s skin as 2D images are acquired at regular spatial intervals
so they are parallel and uniformly spaced at 100-μm intervals over a
length of up to 14 mm. The predefined parallel geometry of the 3D
images facilitates 3D image reconstruction. A full 2D and 3D image
acquisition session requires less than 3 minutes.
PA imaging was performed using VisualSonics Vevo LAZR PA
Imaging System (VisualSonics Inc., Ontario, Canada). The MS-400
transducer was integrated into a special housing that allowed both the
ultrasound micro-coaxial cable and optical fiber bundles to be
incorporated into the same package. An initial 3D survey of the
tumor was performed in B-mode. A region of interest (ROI) was
drawn around the tumors, and average values of sO2 were calculated
within instrument-specified ROI. Data were collected in 3D
by scanning the transducer with the 3D motor while capturing 2D
PA images.
Tumor Volume and Growth Curve Measurements
The 3D ultrasound images were processed and analyzed for
calculation of tumor volume using Vevo Lab 1.7.0 software
(VisualSonics Inc., Ontario, Canada). The reconstructed 3D image
is displayed in a dynamic cube view format as a polyhedron with the
appropriate image displayed on each face. The tumor boundaries were
manually delineated in parallel slices in the 3D serials. The areas of
the outlined contours were summed and multiplied by the interslice
distance to compute tumor volume. Exponential volume growth
curves were fit by linear regression; coefficients of determination were
computed to assess the goodness of fit of the exponential function
using a GraphPad Prism 6 package (GraphPad, La Jolla, CA). Upon
mouse sacrifice at the end of experiments, primary prostate tumors
were harvested and measured by a caliper. The gross tumor volumes
were calculated as follows: length × width × height × 0.52 (in
millimeters) [10]. Agreement of the gross pathology and ultrasound
volume measurements was assessed using the graphical method of
Bland and Altman [11].Results
Ultrasound As a Useful Imaging Tool in Monitoring Prostate
Tumor Growth in the Orthotopic Mouse Model
Ultrasound imaging was conducted starting from 1 week after the
cell inoculation. Orthotopic prostate tumor was found to be
detectable by ultrasound as early as 2 weeks after the cell inoculation,
suggesting great sensitivity of ultrasound in CaP detection. Figure 1
illustrates several characteristics of the prostate and its surrounding
accessory organs (A) as well as prostate tumor (B) that can be observed
using 2D ultrasound imaging. Firstly, prostate tumor shows a
hypoechoic ring surrounding a central region of heterogeneous
texture. The appearance of a hypoechoic outer ring appears to be an
important factor that allows prostate tumors to be detected in
ultrasound images. Secondly, the male urinary and reproductive
accessory organs such as bladder and seminal vesicles are recognizable
Figure 1. Representative 2D ultrasound images of prostate and prostate tumor. Prostate parts and its surrounding accessory organs (A),
and prostate tumor (B) can be observed using 2D ultrasound imaging. Prostate tumor was delineated with yellow triangles; the red star
(hypoechoic area) indicates hemorrhage; the blue arrow (hyperechoic area) indicates calcification formed within the tumor.
Photoacoustic images were taken 3 weeks post cell inoculation. In Oxy-Hemo mode, blue indicates 0% O2 saturation, whereas red
indicates 100% O2 saturation (C). Avr, average; DLP, dorsolateral prostate; HbT, hemoglobin concentration; SV, seminal vesicle; UB,
urinary bladder.
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Finally, it was found that normal prostate is brighter than
surrounding healthy tissues in the ultrasound images, so normal
prostate tissue is unlikely to be misclassified as cancerous by
ultrasound imaging.
PA Ultrasound Imaging As a Useful Tool in Monitoring
Microenvironmental Changes in the CaPOrthotopicMouseModel
Figure 1C shows PA functional maps superimposed on 2D
B-mode images including area of ROI, average sO2, and average
hemoglobin concentration of ROI as well as tumor volume, tumor
average sO2, and tumor average after 3D rendering. It also enables
display of blood oxygenation surrounding the tumor and tumor
vasculature and angiogenesis.
Longitudinal Imaging of Tumor Progression
Figure 2, A–E shows the representative 2D images from 3D scans
of four different time points in a mouse that developed a large ventral
prostate tumor. The tumor was first detected 2 weeks post cell
inoculation, designated week 0. Figure 2A shows a 2D ultrasound
image obtained at week 0. Figure 2, B–E shows the images of the
same tumor on week 1, 2, 3, and 4, respectively. 3D scans were
loaded into the analysis software and reconstructed, and then the
tumor was manually outlined. Figure 2, F–J depicts representative
images of 3D rendering of CaP from the same mouse at different time
points of week 0, 1, 2, 3, and 4. Figure 2K presents the gross
pathology tumor specimen that was harvested on week 5. The
hematoxylin and eosin slide demonstrates an extensive, poorlydifferentiated high-grade CaP xenograft tissue (Figure 2L). Longitu-
dinal tumor volume measurements were obtained from all eight mice.
The representative tumor volumes from three mice were plotted
against time in Figure 3A. The results indicate that the exponential
growth functions fit the volume data well (r2 = 0.948, 0.955, and
0.953 for mouse 1, 2, and, 3, respectively).
Agreement of Ultrasound Imaging and Gross Pathology Volume
Measurements
Paired volume measurements obtained from 3D ultrasound images
and gross pathology specimens harvested at the end of experiment from
eight mice are plotted in Figure 3B. The plot shows a straight-line fit to
the data obtained by linear regression. Pearson’s correlation coefficient is
r = 0.95, indicating a significant (P b .001) correlation between the
ultrasound and gross pathology measurement. The Bland-Altman
scatter plot (Figure 3C) shows the close agreement between ultrasound
and gross pathology at the end of the experiment. The difference was
plotted against the average, and the SD of the difference (bias) was 11.6
mm3, which was small compared with the true volume of the tumors.
Discussion
The development of imaging equipment and reporter probes has
improved researchers’ ability to study mouse models of CaP, such as
the orthotopic model. These technologies can now be used to
continuously monitor in vivo tumor development, providing data
that traditionally used to be unavailable premortem, such as tumor
volume and growth curves. Ideally, a small-animal cancer imaging












Figure 2. Longitudinal 2D and 3D ultrasound images of prostate tumors with gross pathology and histopathology. (A–E) Transverse
prostate tumor (outlined by yellow line) obtained from the same mouse on five different time points (week 0-4). (F–J) 3D reconstructed
prostate tumor (outlined by blue wire) acquired from the same mouse on five different time points (week 0-4). (K) Gross specimen of the
same tumor harvested at the end of the experiment. (L) Hematoxylin and eosin slide from the same specimen shows a high-grade, poorly
differentiated (yellow arrow) CaP of the same tumor (magnification, ×400).
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inexpensive to purchase, feasible to operate, and easy to maintain.
Furthermore, when frequent longitudinal studies are required, theFigure 3. Exponential growth curves for longitudinal tumor volume m
pathology volume measurements. (A) Prostate tumor volumes from
exponential growth curves, r2 = 0.948, 0.955, and 0.953 for mouse 1
volumes measured by 3D ultrasound imaging and gross pathology w
(C) Bland-Altman analysis of agreement of eight paired tumor volum
was plotted.imaging examination should be harmless and noninvasive to the
animal so that as many imaging sessions can be done as necessary
without imposing the risk to the animals.easurements and agreement of 3D ultrasound imaging and gross
three representative mice were plotted against time, with fitted
, 2, and 3, respectively. (B) Good correlation of eight paired tumor
as demonstrated by linear regression (Pearson’s r= 0.95, P b .001).
e measurements by 3D ultrasound imaging and gross pathology
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characteristics required for a small-animal imaging technology
mentioned above. Ultrasound is nonionizing, is noninvasive, and
provides a good soft-tissue contrast without the need of injection of
imaging developing agents. In animals, it has been used to monitor
interventional procedures such as in utero transgene or cell
implantations [12], and tumor development of various kinds of
cancers including breast cancer [13], hepatocarcinoma [14], ovarian
cancer [15], and CaP [16]. The system used in this study permits a
rapid survey of mouse CaP, thereby improving the efficiency of
multiple-animal longitudinal studies.
In this study, we used 2D and 3D ultrasound imaging to monitor the
tumor growth in an orthotopic tumor xenograft model and compared the
acquired data to the true tumor volume. Our results indicate that
ultrasound imaging, whether in 2D or 3D mode, is able to clearly detect
CaP in the orthotopic mouse model. Our current findings also showed a
good correlation and agreement of tumor volumes measured by 3D
ultrasound imaging and gross pathology. In addition, this study also
demonstrated that repeated imaging sessions had beenwell tolerated by the
mice, suggesting that 3D ultrasound imaging is an ideal technique to
monitor longitudinal tumor growth in the orthotopic CaP mouse model.
Furthermore, we also found that the latest development of PA imaging is
well suited to small-animal imaging. Because it is a lately developed
technology, not many investigations have been done regarding this
methodology. The characteristics of PA can be used in the tumor
microenvironment studies, such as hypoxia, angiogenesis, and tumor
response to cancer therapies.
Challenges of ultrasound imaging include smaller penetration depth,
inability to image air-filled organs, vulnerability of ultrasound of easily
being scattered, and operator-subjective image variability. Also, it does not
produce whole-body cross-sectional images as computed tomography and
magnetic resonance imaging (MRI) do. Moreover, it is hard to use
ultrasound to detect CaP tumorigenesis in an early stage (1 week post cell
inoculation) as well as potential metastasis, whereas MRI was able to
provide cross-sectional images of a prostate tumor as early as 1 week and
any suspect metastasis could easily be distinguished. Lastly, the tumor
volume measurement in 3D imaging is largely dependent on an operator.
MRI is a versatile imaging tool with high soft-tissue contrast and can be
used to obtain anatomical, physiological, andmolecular information about
tumors. Our group used T2-fluid attenuation inversion recovery (FLAIR)
MRI sequence to monitor the tumor growth in an orthotopic CaP model
inNODSCIDmice.We found that CaP tumorigenesis could be detected
as early as 1 week post cell inoculation and tumor is better delineated from
surrounding anatomies (unpublished data). High-resolutionMRI is by far
one of the most useful imaging tools to visualize tumors size, location,
metastatic burden, and phenotype. Investigations on comparison of
ultrasound and MRI in monitoring tumor growth, as well as on using
MRI to monitor longitudinal tumor growth, are ongoing in our group.
This study demonstrates that ultrasound is a feasible, economical,
and sensitive method to monitor longitudinal tumor growth in an
orthotopic CaP mouse model. Future investigations should be directed
to improve the image quality and field of view, automate the tumor
volume measurement to address the current challenges, and optimize
PA imaging operation and develop other new molecular imaging
technologies using ultrasound to supplement existing modalities.Acknowledgements
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